RecruitingPhase 2NCT06956326
Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation
Sponsor
Lars Hvid
Enrollment
64 participants
Start Date
May 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The overall purpose of this project is to develop and test an infrastructure that can ensure early and specialized rehabilitation for individuals with multiple sclerosis (MS) on their path to recovery from a relapse. If this project proves successful, it can therefore help optimize clinical practice and provide a significant contribution to the treatment of relapsing-remitting sclerosis.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- admitted to the Danish MS Hospitals for an inpatient rehabilitation stay
- confirmed motor relapse (within the past 6 months) by a neurologist, with disability/ functional interference characterized by change in pyramidal, and/or cerebellar functional scores of 2 or higher
- completed steroid or other acute relapse treatment, if prescribed
- age over 18 years
Exclusion Criteria3
- more than 6 months since onset of motor relapse
- medical conditions or substantial cognitive impairments that hinder participation in the study (e.g. inability to perform or understand the intensive rehabilitation)
- pregnancy
Interventions
BEHAVIORALIntensive rehab
Frequent moderate-to-high intensity physical therapy, provided by local physiotherapists.
BEHAVIORALUsual care
Usual care physiotherapy
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06956326
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT072253611 location